Apogee Therapeutics shareholders approved AbbVie’s planned acquisition of the company for approximately $10.9 billion. This vote clears a major hurdle for the deal intended to bolster AbbVie’s immunology portfolio.
The acquisition adds zumilokibart, a candidate for atopic dermatitis, to AbbVie's clinical pipeline. This move supports the company’s strategy to manage the lifecycle of its blockbuster drug, Humira.
AbbVie’s current immunology leaders, Skyrizi and Rinvoq, continue to report strong sales growth. These results reinforce the company’s expansion within the immunology sector.